Availability

IRESSA (gefitinib) is currently approved for use in advanced NSCLC in the following countries.

Argentina	Australia	Bahrain
Canada*	Chile	China
Curacao	Dominican Republic	El Salvador
Guatemala	Honduras	Hong Kong
India	Indonesia	Israel
Japan	South Korea	Malaysia
Mexico	New Zealand	Nicaragua
Panama	Peru	Qatar
Russia	The Philippines	Serbia & Montenegro
Singapore	Sri Lanka	Switzerland*
Taiwan	Thailand	United Arab Emirates
Uruguay	USA*	Venezuela

* Please note that the use of IRESSA is restricted in the USA, Canada and Switzerland.

For further information, please contact your local AstraZeneca office by clicking on the links above.